Udai Kammula, MD
Enriched profileProfessor of Surgery and Director, Solid Tumor Cell Therapy Program, UPMC Hillman Cancer Center · University of Pittsburgh
Udai Kammula is Professor of Surgery and Director, Solid Tumor Cell Therapy Program, UPMC Hillman Cancer Center at University of Pittsburgh. OpenAlex indexes 192 publications with 30,725 citations (h-index 53); ClinicalTrials.gov lists 4 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Surgical Oncology profiles in the findmyKOL directory.
Data verified 11 Oct 2026
Overview
Updated 13 Oct 2026
Udai Kammula, M.D., is Professor of Surgery and Director, Solid Tumor Cell Therapy Program, UPMC Hillman Cancer Center at University of Pittsburgh / UPMC Hillman Cancer Center. The public record shows 192 publications with 30,725 citations (h-index 53), centered on Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 1 companies, 2 NIH-funded awards (2019–2026).
- Most recent indexed publication: 2025 · Science signaling
- Top research focus: Immunotherapy and Immune Responses
- 4 registered trials on ClinicalTrials.gov
- Open Payments reporting from 1 companies
Generated from the cited public record · current as of 13 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 4 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 81.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 13 Oct 2026
Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:
- Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Sponsor: Udai Kammula
- Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
Sponsor: Udai Kammula
- Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
Sponsor: Udai Kammula
Industry payments
Updated 13 Oct 2026
1 company reported payments to CMS in program years 2022–2022. These are public disclosures, not judgments. The latest:
- Medtronic, Inc.Program year20221 payment
Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
100%Short-acting sulfonamides100%Sulfamethoxazole-Trimethoprim100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 13 Oct 2026
2 NIH research awards on record, funded 2019–2026 per NIH RePORTER. The latest:
- Postdoctoral Research Training in Biotherapy of Cancer
University of Pittsburgh at Pittsburgh
FY2026$239,475T32CA113263 - Postdoctoral Research Training in Biotherapy of Cancer
University of Pittsburgh at Pittsburgh
FY2025$297,948T32CA113263 - Postdoctoral Research Training in Biotherapy of Cancer
University of Pittsburgh at Pittsburgh
FY2024$293,213T32CA113263
Congress activity
Updated 13 Oct 2026
6 congress contributions (2010–2018) across AACR, ASCO per OpenAlex. The most recent:
- Treatment of metastatic human papillomavirus-associated epithelial cancers with adoptive transfer of tumor-infiltrating T cells.
ASCO Annual Meeting
ASCO2018Co-author - Abstract CT003: A phase I study of an HLA-DPB1*0401-restricted T-cell receptor targeting MAGE-A3 for patients with metastatic cancer
AACR (meeting unresolved)
AACR2016Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 13 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility.
Nature communications
Article2024 - Genome-wide gain-of-function screening characterized lncRNA regulators for tumor immune response.
Science advances
Article2022
Most-cited works
by citation count (OpenAlex)- 01Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesArticle2,606 citations2006
- 02
- 03
- 04
- 05
Network
Updated 13 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 13 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
enterprises.upmc.com
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →enterprises.upmc.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 13 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
University of Maryland School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.upmc.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.upmc.com ↗
- BA
Johns Hopkins University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →broadcastmed.com ↗
Editorial & leadership roles
journal and society appointments- Fellow
American College of Surgeons (FACS)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.upmc.com ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.upmc.com ↗
Media & interviews
press, podcasts and appearances- Interviewed on Pittsburgh's Action News
December 28, 2023, about a new cancer treatment for a UPMC patient
2023provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →enterprises.upmc.com ↗ - Featured speaker on TIL therapy advances
UPMC Enterprises All Hands
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →enterprises.upmc.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Sally Wenzel, MD
University of Pittsburgh
Mary Phillips, MD
University of Pittsburgh
Jared Magnani, MD, MSc
University of Pittsburgh
Jorge Gonzalez-Martinez, MD
University of Pittsburgh
Jedd Wolchok, MD
Weill Cornell Medicine
Mario Sznol, MD
University of Miami Miller School of Medicine
Kevin Brown, MD
National Cancer Institute
Patrick Ott, MD
Dana-Farber Cancer Institute